# EDGAR Filing Document

**Accession Number:** 0001382101
**File Stem:** 0001193125-26-131936
**Filing Date:** 2026-3
**Character Count:** 2727
**Document Hash:** 341f6e8262be8f71e885858a5850e0cf
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-131936.hdr.sgml**: 20260505

**ACCESSION NUMBER**: 0001193125-26-131936

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260330

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** SUTRO BIOPHARMA, INC.
- **CENTRAL INDEX KEY:** 0001382101
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 452441988
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 111 OYSTER POINT BLVD.
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080
- **BUSINESS PHONE:** 650-392-8412

**MAIL ADDRESS:**
- **STREET 1:** 111 OYSTER POINT BLVD.
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** SUTRO BIOPHARMA INC
- **DATE OF NAME CHANGE:** 20061127

**SUTRO BIOPHARMA, INC.** 

111 Oyster Point Blvd.

South San Francisco, CA 94080

March 30, 2026

**<u>VIA EDGAR</u>**

United States Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, DC 20549

---

| | |
|:---|:---|
| Attention: | Office of Life Sciences |
| Re: | Sutro Biopharma, Inc.<br> Registration Statement on Form S-3<br> Filed March 23, 2026<br> File No. 333-294541 |

---

Requested Date: April 1, 2026

Requested Time: 4:00 p.m. Eastern Time

Ladies and Gentlemen:

Sutro Biopharma, Inc. (the "***Registrant***") hereby requests that the Securities and Exchange Commission (the "***Commission***") take appropriate action to make the above-captioned Registration Statement on Form S**-**3 effective at the "Requested Date" and "Requested Time" set forth above or as soon thereafter as practicable, or at such later time as the Registrant may orally request via telephone call to the staff of the Commission.

The Registrant hereby authorizes Amanda Rose or Ryan Mitteness, both of whom are attorneys with the Registrant's outside legal counsel, Fenwick & West LLP, to orally modify or withdraw this request for acceleration.

The Registrant requests that it be notified of such effectiveness by a telephone call to Ms. Rose at (206) 389-4553 or, in her absence, to Mr. Mitteness at (206) 389-4533.

\* \* \*

------

---

| | |
|:---|:---|
| Sincerely, | Sincerely, |
| **SUTRO BIOPHARMA, INC.** | **SUTRO BIOPHARMA, INC.** |
| By: | */s/ Gregory Chow* |
|  | Gregory Chow |
|  | Chief Financial Officer |

---

cc: Jane Chung, Chief Executive Officer

**Sutro Biopharma, Inc.** 

Amanda Rose, Esq.

Ryan Mitteness, Esq.

**Fenwick & West LLP** 

[Signature Page to Company Acceleration Request Letter]